ABCB1 polymorphisms and steroid treatment in children with idiopathic nephrotic syndrome

British Journal of Biomedical Science

Volumn 74, Issue 1, 2017, Pages 36-41

  Safan, Manal A ^a   Elhelbawy, Nesreen G ^a   Midan, Dina A ^a   Khader, Heba F ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

ABCB1 gene; idiopathic nephrotic syndrome; real time PCR

Indexed keywords

ALBUMIN; BILIRUBIN; CHOLESTEROL; CREATININE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; UREA; ABCB1 PROTEIN, HUMAN; GLUCOCORTICOID;

ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE FREQUENCY; GENOTYPE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; ONSET AGE; PRIORITY JOURNAL; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UREA BLOOD LEVEL; DRUG RESISTANCE; GENETICS; ODDS RATIO; PRESCHOOL CHILD;

ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; GENOTYPE; GLUCOCORTICOIDS; HUMANS; MALE; NEPHROTIC SYNDROME; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISOLONE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84990932235     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2016.1220707     Document Type: Article

References (31)

1. Hacihamdioglu DO, Kalman S, Gok F. Long-term results of children diagnosed with idiopathic nephrotic syndrome; single center experience. Turk. Pediatr. Ars. 2015;50:37–44.10.5152/tpa
2. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362:629–639.10.1016/S0140-6736(03)14184-0
3. Hayslett JP, Kashgarian M, Bensch KG, et al. Clinicopathological correlations in the nephrotic syndrome due to primary renal disease. Medicine. 1973;52:93–120.10.1097/00005792-197303000-00001
4. Kriz W, Elger M, Nagata M, et al. The role of podocytes in the development of glomerular sclerosis. Kidney Int. Suppl. 1994;45:64–72.
5. Bennett MR, Pordal A, Haffner C, et al. Urinary vitamin D-Binding protein as a biomarker of steroid-resistant nephrotic syndrome. Biomarker Insights. 2016;13(11):1–6.10.4137/BMI
6. McBryde KD, Kershaw DB, Smoyer WE. Pediatric steroid-resistant nephrotic syndrome. Curr. Prob. Pediatr. 2001;31:280–307.10.1067/mps.2001.119800
7. Subramanya A, Houghton D, Watnick S. Steroid-responsive idiopathic glomerular capillary endotheliosis:case report and literature review. Am. J. Kidney Dis. 2005;45:1090–1095.10.1053/j.ajkd.2005.03.010
8. Cizmarikova M, Podracka L, Klimcakova L, et al. MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children:preliminary results. Med. Sci. Monit. 2015;6:59–68.
9. Mortazavi F, Khiavi YS. Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome:a single-center experience in northwest Iran. Ther. Clin. Risk Manag. 2011;7:167–171.10.2147/TCRM
10. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Ann. Rev. Pharmacol. Toxicol. 2003;43:285–307.10.1146/annurev.pharmtox.43.100901.140233
11. Chen Y, Zhao Y, Wang C, et al. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistence associated with P-glycoprotein in human leukemia K562 cells. Med. Sci. Monit. 2012;18:383–388.
12. Xu P, Jiang ZP, Zhang BK, et al. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology. 2008;82:221–227.10.1159/000156488
13. Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? Am. J. Kidney Dis. 2003;41:1163–1169.10.1016/S0272-6386(03)00348-2
14. Ibrahim SE, Abdel-Salam IE, Galal EN, et al. Histological patterns of idiopathic steroid resistant nephrotic syndrome in Egyptian children:a single centre study. J. Nephropathol. 2013;2:53–60.10.5812/nephropathol
15. Jaiswal A, Prasad N, Agarwal V, et al. Regulatory and effector T cells changes in remission and resistant state of childhood nephrotic syndrome. Indian J. Nephrol. 2014;24:349–355.
16. Chiou YH, Wang LY, Wang TH, et al. Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr. Nephrol. 2012;27:1511–1517.10.1007/s00467-012-2182-0
17. Choi HJ, Cho HY, Ro H, et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr. Nephrol. 2011;26:1981–1988.10.1007/s00467-011-1903-0
18. Youssef DM, Attia TA, El-Shal AS, et al. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome:impact on susceptibility and response to steroids. Gene. 2013;530:201–207.10.1016/j.gene.2013.08.045
19. Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflammation Bowel Dis. 2004;10:578–583.10.1097/00054725-200409000-00012
20. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, et al. P-glycoprotein in autoimmune diseases. Autoimmune. Rev. 2004;3:188–192.10.1016/j.autrev.2003.08.002
21. Wasilewska A, Zalewski G, Chyczewski L, et al. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr. Nephrol. 2007;22:44–51.10.1007/s00467-006-0275-3
22. Jafar T, Prasad N, Agarwal V, et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol. Dial. Transplant. 2011;26:3968–3974.10.1093/ndt/gfr150
23. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad Sci. USA. 2000;97:3473–3478.10.1073/pnas.97.7.3473
24. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–528.10.1126/science.1135308
25. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12:437–450.10.1097/00008571-200208000-00004
26. Salama NN, Yang Z, Bui T, et al. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P‐gp substrate transport in recombinant LLC‐PK1 cells. J. Pharm. Sci. 2006;95:2293–2308.10.1002/jps.20717
27. Schuetz EG, Schuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch. Biochem. Biophys. 1992;294:206–214.10.1016/0003-9861(92)90159-T
28. Anttila S, Hukkanen J, Hakkola J, et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am. J. Respir. Cell Mol. Biol. 1997;16:242–249.10.1165/ajrcmb.16.3.9070608
29. Sakaeda T. MDR1 genotype-related pharmacokinetics:fact or fiction? Drug Metabol. Pharmacokinet. 2005;20:391–414.10.2133/dmpk.20.391
30. Marchetti S, Mazzanti R, Beijnen JH, et al. Concise review:clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12:927–941.10.1634/theoncologist.12-8-927
31. Joshi S, Andersen R, Jespersen B, et al. Genetics of steroid-resistant nephrotic syndrome:a review of mutation spectrum and suggested approach for genetic testing. Acta Paediatr. 2013;102:844–856.10.1111/apa.12317